No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AZN240726C92000
- 0.06
- -0.06-50.00%
15min DelayClose Jul 24 16:00 ET
0.06High0.04Low
0.04Open0.12Pre Close45 Volume23 Open Interest92.00Strike Price182.00Turnover90.63%IV15.49%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type0.0222Delta0.0095Gamma1771.33Leverage Ratio-0.0415Theta0.0001Rho39.33Eff Leverage0.0033Vega
Intraday
- 5D
- Daily
News
Earnings From American & Southwest, Q2 GDP Data: What to Watch
Unusual Options Activity: ACI, AZN and Others Attract Market Bets, ACI V/OI Ratio Reaches 208.3
AstraZeneca Q2 2024 Earnings Preview
Notable Earnings Before Thursday's Open
AstraZeneca Grows Oncology Portfolio With Pinetree's EGFR Degrader
UBS Sticks to Its Sell Rating for AstraZeneca (AZN)
Comments
$AstraZeneca(AZN.US$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24 (sBLA)
$BeiGene(BGNE.US$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas (1L)
‣ PDUFA: July 2024 (sBLA)
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24 (sBLA)
$BeiGene(BGNE.US$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas (1L)
‣ PDUFA: July 2024 (sBLA)
3
$AstraZeneca(AZN.US$ Time for another ATH
Don't miss out! 🎯👇
$Phathom Pharmaceuticals(PHAT.US$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA: 7/19/24 (NDA)
$AstraZeneca(AZN.US$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24(sBLA)
$BeiGene(BGNE.US$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas
‣ PDUFA: July 2024 (BLA)
$Phathom Pharmaceuticals(PHAT.US$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA: 7/19/24 (NDA)
$AstraZeneca(AZN.US$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24(sBLA)
$BeiGene(BGNE.US$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas
‣ PDUFA: July 2024 (BLA)
5
1 PDUFA this week! 🔥
$Arcutis Biotherapeutics(ARQT.US$ : pending decision 🤔
⇨ ARQ-151 topical roflumilast cream
‣ Atopic Dermatitis (aged 6 & older children)
‣ PDUFA date: 7/7/24 (sNDA)
Upcoming PDUFAs & AdCom in July: 📅👇
$Phathom Pharmaceuticals(PHAT.US$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA date: 7/19/24 (NDA)
$AstraZeneca(AZN.US$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom date: 7/25/24(sBLA)
$BeiGene(BGNE.US$ :...
$Arcutis Biotherapeutics(ARQT.US$ : pending decision 🤔
⇨ ARQ-151 topical roflumilast cream
‣ Atopic Dermatitis (aged 6 & older children)
‣ PDUFA date: 7/7/24 (sNDA)
Upcoming PDUFAs & AdCom in July: 📅👇
$Phathom Pharmaceuticals(PHAT.US$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA date: 7/19/24 (NDA)
$AstraZeneca(AZN.US$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom date: 7/25/24(sBLA)
$BeiGene(BGNE.US$ :...
6
🔥 July: 3 PDUFAs & 1 AdCom
$Arcutis Biotherapeutics(ARQT.US$ : ARQ-151 topical roflumilast cream
$Phathom Pharmaceuticals(PHAT.US$ : VOQUEZNA® (vonoprazan)
$AstraZeneca(AZN.US$ : Imfinzi + chemotherapy - AdCom
$BeiGene(BGNE.US$ : TEVIMBRA (tislelizumab)
$Arcutis Biotherapeutics(ARQT.US$ : ARQ-151 topical roflumilast cream
$Phathom Pharmaceuticals(PHAT.US$ : VOQUEZNA® (vonoprazan)
$AstraZeneca(AZN.US$ : Imfinzi + chemotherapy - AdCom
$BeiGene(BGNE.US$ : TEVIMBRA (tislelizumab)
7
2
Read more